“These new rules are unduly onerous, expensive, and impractical. Even if they are ultimately implemented, it is unlikely that they would greatly facilitate clinical cannabis research in the United States.”
A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis.
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses.
“For the past three years, the DEA has failed to take any steps to follow through on its promise to facilitate clinical cannabis research, and today’s announcement makes it clear that this foot-dragging will continue,” NORML Executive Director Erik Altieri said.
Federal agents seized fewer total marijuana plants in 2018, but made more arrests for cannabis-related offenses, according to annual data compiled by the US Drug Enforcement Administration.
Newly appointed US Attorney General William Barr is being urged to review more than two-dozen pending applications for federal marijuana grow licenses which have languished before the agency for over two years.
Seizures of indoor and outdoor cannabis crops in the United States fell nearly 40 percent between the years 2016 and 2017, according to annual data compiled by the US Drug Enforcement Administration.
In testimony before Congress last week, by DEA acting administrator Robert Patterson opined that the medicalization of cannabis is exacerbating opioid abuse. But when prompted to provide evidence in support of the agency’s position, he acknowledged that he could not.
A bipartisan coalition of over two-dozen federal lawmakers, including House Judiciary Chairman Bob Goodlatte (R-VA) and Matt Gaetz (R-FL), are backing newly introduced legislation — The Medical Cannabis Research Act of 2018 — to facilitate federally-approved clinical trials involving cannabis. Passage of this act would end the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes by requiring the licensing of additional manufacturers.